# Meike Brinker

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/meike-brinker/

## Facts

| Field | Value |
| --- | --- |
| Citations | 1,352 |
| Field | Hormonal Regulation and Hypertension |
| h-index | 18 |
| i10-index | 34 |
| Last Known Institution | Brigham and Women's Hospital |
| OpenAlex ID | https://openalex.org/A5052649260 |
| ORCID iD | 0000-0002-1560-9535 |
| Works | 108 |

## Researcher papers

Showing 12 of 14.

- [Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes](https://scholariq.org/papers/finerenone-with-empagliflozin-in-chronic-kidney-disease-and-type-2-diabetes/)
- [Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes](https://scholariq.org/papers/finerenone-in-heart-failure-and-chronic-kidney-disease-with-type-2-diabetes-fine/)
- [A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes](https://scholariq.org/papers/a-prespecified-exploratory-analysis-from-fidelity-examined-finerenone-use-and/)
- [Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial](https://scholariq.org/papers/design-and-baseline-characteristics-of-the-finerenone-in-addition-to-standard-of/)
- [Finerenone and Kidney Outcomes in Patients With Heart Failure](https://scholariq.org/papers/finerenone-and-kidney-outcomes-in-patients-with-heart-failure/)
- [Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure](https://scholariq.org/papers/effects-of-the-nonsteroidal-mra-finerenone-with-and-without-concomitant-sglt2/)
- [Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes](https://scholariq.org/papers/outcomes-with-finerenone-in-participants-with-stage-4-ckd-and-type-2-diabetes/)
- [Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis](https://scholariq.org/papers/finerenone-and-effects-on-mortality-in-chronic-kidney-disease-and-type-2/)
- [Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression](https://scholariq.org/papers/development-and-validation-of-a-new-hierarchical-composite-end-point-for/)
- [Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study](https://scholariq.org/papers/finerenone-in-patients-with-chronic-kidney-disease-and-type-2-diabetes-according/)
- [Clinical characteristics and disease outcomes in non-diabetic chronic kidney disease: retrospective analysis of a US healthcare claims database](https://scholariq.org/papers/clinical-characteristics-and-disease-outcomes-in-non-diabetic-chronic-kidney/)
- [Finerenone and eGFR Slope across Different Levels of Baseline Albuminuria and eGFR](https://scholariq.org/papers/finerenone-and-egfr-slope-across-different-levels-of-baseline-albuminuria-and/)

## Researcher topics

- [Hormonal Regulation and Hypertension](https://scholariq.org/topics/hormonal-regulation-and-hypertension/)
- [Heart Failure Treatment and Management](https://scholariq.org/topics/heart-failure-treatment-and-management/)
- [Blood Pressure and Hypertension Studies](https://scholariq.org/topics/blood-pressure-and-hypertension-studies/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)

## Researcher university

- [Brigham and Women's Hospital](https://scholariq.org/institutions/brigham-and-women-s-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.